GLP-1 Savings & TrumpRx (2026): The $499 Hack

Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through partner links, at no extra cost to you. Editorial independence preserved — recommendations based on provider compliance and patient outcomes, not commission rates. This article is informational and is not medical advice.

If you have looked into paying for a GLP-1, you have met the thicket: manufacturer savings cards, NovoCare and LillyDirect self-pay programs, the new TrumpRx portal, patient assistance programs, pharmacy discount cards, the Medicare GLP-1 Bridge. The names overlap, the rules differ, and the marketing around each one implies it might be the answer for you.

The most common mistake is treating these as a menu to combine — hunting for a way to layer a savings card on top of a self-pay price on top of a coupon. With one exception, they do not combine. Each program is built for a single situation, defined mostly by your insurance status. They are less a menu than a set of separate lanes, and the useful question is not “how do I combine these” but “which lane am I in.” This guide sorts them.

If You Have Commercial Insurance — the Savings Cards

If you have commercial or employer-sponsored insurance, the manufacturer savings card is your route. Every brand GLP-1 has one — the Ozempic, Wegovy, Mounjaro and Zepbound savings cards — and the headline is consistent: for a patient whose commercial plan covers the drug, the card can bring the monthly copay down to as little as $25.

Two rules matter. First, there is usually a second tier. If you have commercial insurance but your specific plan does not cover the GLP-1, the card still applies — but the discount is far smaller, and the out-of-pocket cost lands well above the $25 figure. The card reduces what you owe; it cannot conjure coverage that is not there.

Second, and this is the rule that surprises people: manufacturer savings cards cannot be used with government insurance. Federal law prohibits it. If you have Medicare, Medicaid, Tricare or VA benefits, the savings card is closed to you regardless of income — a different lane applies, covered below.

Savings cards also carry caps and expiration dates — typically an annual savings maximum and a calendar-year expiry — so they are best understood as a strong but bounded and temporary benefit. You enroll through the specific drug’s official savings-card website.

If You’re Paying Cash — Self-Pay Programs and TrumpRx

If you are uninsured, or insured without GLP-1 coverage and choosing to pay cash, the relevant programs are the manufacturers’ own self-pay channels — and the federal TrumpRx portal that sits in front of them.

NovoCare, Novo Nordisk’s self-pay pharmacy, and LillyDirect, Eli Lilly’s, sell their GLP-1s directly to cash-paying patients at prices far below retail list — broadly in the range of $299 to $499 a month for the injectables, and from around $149 for the oral forms, depending on the drug and dose. These are covered drug by drug in our Wegovy and Mounjaro cost guides and the main GLP-1 cost guide.

One more cash-payer tool is the pharmacy discount card — GoodRx, SingleCare and similar services. These can trim the price at the pharmacy counter, but for brand-name GLP-1s the discount is modest, and the resulting price generally does not beat the manufacturers’ own self-pay channels. A discount card is most useful as a fallback for an urgent local pickup; for ongoing treatment, the manufacturer self-pay route usually costs less.

TrumpRx is the part most worth understanding clearly, because it is widely misunderstood. Launched in early 2026 at trumprx.gov, TrumpRx is a federal direct-to-consumer portal — but it is a navigator, not a pharmacy, and not a separate discount program. It does not sell drugs itself; it routes you to the manufacturers’ own direct-to-consumer channels. The cash prices reachable through it — roughly $350 a month for the semaglutide injectables, a little under that for tirzepatide, around $149 for the oral starter doses — are essentially the manufacturer self-pay prices. The administration has said those prices are meant to drift down toward roughly $245 over about two years.

The practical takeaway: TrumpRx is a useful front door, but if you already know about NovoCare or LillyDirect, it is not unlocking a hidden cheaper price beneath them.

If You Have a Low Income — Patient Assistance Programs

Separate from all of the above are the patient assistance programs, or PAPs — the manufacturers’ charity-care channels for people who genuinely cannot afford treatment.

Novo Nordisk runs one; Eli Lilly’s is called Lilly Cares. Both can provide their medication at no cost to patients who qualify, and qualification turns on household income — broadly, an income under roughly 400 percent of the federal poverty level, though you should confirm the current threshold. The other eligibility rules are the part people miss: the PAPs are for patients who are uninsured or on Medicare, and specifically not for those with commercial insurance — the mirror image of the savings cards. They also generally exclude people who qualify for Medicaid.

One pattern is worth knowing. The manufacturers’ assistance programs tend to cover their diabetes-branded drugs but not their weight-loss-branded ones: Novo Nordisk’s program covers Ozempic but not Wegovy; Lilly Cares covers Mounjaro but not Zepbound. So a PAP is a realistic route to free medication mainly for a low-income patient being treated for type 2 diabetes.

If You Have Medicare

Medicare is its own lane, with two fixed facts. The first: as noted above, manufacturer savings cards do not work with Medicare. The second: standard Medicare Part D can cover a GLP-1 when it is prescribed for an approved medical condition — type 2 diabetes, or the cardiovascular or sleep-apnea indications that some of these drugs carry — but not for weight loss alone, which federal law has long excluded.

That weight-loss gap is what the Medicare GLP-1 Bridge addresses. Beginning July 1, 2026, and running through the end of 2027, this temporary CMS program lets eligible Part D beneficiaries get the GLP-1s approved for weight loss — Wegovy, the Zepbound KwikPen, and the oral drug Foundayo — for a flat $50 monthly copay. It operates outside the standard Part D benefit, and other coupons cannot be stacked onto the $50. For a Medicare beneficiary, then, the route is one of: Part D for an on-label medical use, the Bridge for weight loss from mid-2026, a patient assistance program if income is low, or paying cash.

The One Thing That Stacks — HSA and FSA Dollars

Every program above is an either/or — you pick your lane. There is one genuine exception, and it is the most overlooked saving of all.

GLP-1 medications are eligible expenses for Health Savings Accounts and Flexible Spending Accounts. Paying with HSA or FSA money does not lower the sticker price, but because those dollars are set aside before tax, it lowers the real cost — effectively by something like 20 to 35 percent, depending on your tax bracket. And unlike the manufacturer programs, this one layers: you can pay a savings-card copay, a self-pay price, or an ordinary insurance copay with HSA or FSA funds. If you have access to either kind of account, using it for a GLP-1 stacks on top of whatever lane you are already in.

Frequently Asked Questions

Can I use a GLP-1 savings card with Medicare?

No. Federal law prohibits manufacturer savings cards from being used with government insurance — Medicare, Medicaid, Tricare and VA benefits. If you are on Medicare, your routes are standard Part D for an approved medical use, the Medicare GLP-1 Bridge for weight loss from July 2026, a patient assistance program if your income is low, or paying cash.

Is TrumpRx cheaper than buying direct from the manufacturer?

Not really. TrumpRx is a navigator portal, not a pharmacy and not a separate discount program. It routes you to the manufacturers’ own self-pay channels, so the prices you reach through it are essentially the NovoCare and LillyDirect self-pay prices. It is a convenient front door, not a hidden lower price.

Can I stack a savings card with a self-pay discount?

Generally no. The savings card, self-pay programs, patient assistance and the Medicare Bridge are alternative paths, not combinable ones — you use the single lane that matches your situation. The one real exception is HSA or FSA money, which can be used to pay for a GLP-1 on top of any of these routes.

What if I have a low income and no insurance?

Look at the patient assistance programs — Novo Nordisk’s and Eli Lilly’s Lilly Cares. If your household income is under roughly 400 percent of the federal poverty level, they can provide the medication at no cost. Note that these programs mainly cover the diabetes-branded drugs, Ozempic and Mounjaro, rather than the weight-loss brands.

Which program is the cheapest?

There is no universal answer — only a cheapest route for your situation. A commercially insured patient whose plan covers the drug pays as little as $25 with the savings card. A low-income uninsured patient treated for diabetes may pay nothing through a patient assistance program. A Medicare beneficiary pursuing weight loss pays $50 through the Bridge from July 2026. A cash payer turns to manufacturer self-pay or compounded options. Find your lane first.

The Bottom Line

The GLP-1 cost-savings landscape looks chaotic because it genuinely is several different systems wearing similar names. But the logic underneath is simple: each program serves one insurance situation. Commercial insurance points you to the savings card; no insurance and a low income, to a patient assistance program; cash, to the manufacturer self-pay channels that TrumpRx is a front door to; Medicare, to Part D and the new GLP-1 Bridge.

They are lanes, not a stack — with HSA or FSA dollars the one lever that layers on top of any of them. Identify your lane first, and the confusing thicket resolves into a single, answerable question.

This article is general information, not medical or financial advice. Programs, prices and eligibility rules reflect the situation as of May 2026 and change frequently; confirm current details with the manufacturer, CMS, your insurer or your pharmacy before making decisions.